NURS 6521 | Advanced Pharmacology
NURS 6521 Advanced Pharmacology
Midterm Examination 2026/2027 |
Verified Questions
NURS 6521 | Advanced Pharmacology | University-Level Advanced Practice Nursing Students
100 Verified Questions | 4 Core Domains | Academic Year 2026/2027
Prepared by
NURS 6521 | Advanced Pharmacology
Midterm Comprehensive Examination Actual Exam | Academic Year 2026/2027
NURS 6521 Advanced Pharmacology Midterm Examination 2026/2027 | Verified Questions
,INTRODUCTION
This midterm comprehensive examination contains exactly 100 original verified questions designed for
University-Level Advanced Practice Nursing students enrolled in NURS 6521 Advanced Pharmacology.
The questions are distributed equally across four core domains: Pharmacologic Principles and
Pharmacokinetics (25 questions), Cardiovascular and Respiratory Pharmacology (25 questions),
Neurological, Psychiatric, and Pain Management Pharmacology (25 questions), and Endocrine,
Gastrointestinal, and Musculoskeletal Pharmacology (25 questions). Content is original and aligned with
the official NURS 6521 course objectives for the Academic Year 2026/2027, reinforcing foundational
advanced pharmacology knowledge, clinical prescribing logic, and mechanistic understanding required
for actual exam readiness and clinical proficiency.
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles and Pharmacokinetics
Question 1. A patient with hepatic impairment is prescribed a medication that undergoes
extensive first-pass metabolism. Which pharmacokinetic principle most accurately guides
dose adjustment?
A. Increase the dose because first-pass metabolism is reduced
B. Decrease the dose because bioavailability will be increased
C. Maintain the standard dose because renal clearance compensates
D. Switch to an intravenous formulation only if creatinine clearance falls below 30 mL/min
Correct Answer: B
Rationale: Hepatic impairment reduces first-pass metabolism, increasing oral bioavailability of high-
extraction drugs. Therefore the dose must be decreased to avoid toxicity. This principle is foundational
in advanced pharmacokinetics for nurse prescribers.
Question 2. Which parameter best predicts the time required for a drug to reach steady-
state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Correct Answer: D
Rationale: Steady state is reached after approximately four to five half-lives regardless of dose or
infusion rate. Elimination half-life is therefore the primary determinant of time to steady state.
Question 3. A highly protein-bound drug is administered to a patient with severe
hypoalbuminemia. What change in free (unbound) drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
D. Decreased free fraction because hepatic synthesis of albumin increases
Correct Answer: A
Rationale: Hypoalbuminemia reduces binding sites, elevating the free fraction of highly protein-bound
drugs. The unbound concentration drives pharmacologic effect and toxicity risk, requiring careful
monitoring.
Question 4. Which cytochrome P450 enzyme is responsible for the majority of clinically
significant drug–drug interactions involving oxidative metabolism?
A. CYP2C19
B. CYP2D6
NURS 6521 Advanced Pharmacology Midterm Examination 2026/2027 | Verified Questions
, C. CYP3A4
D. CYP1A2
Correct Answer: C
Rationale: CYP3A4 metabolizes more than 50% of currently prescribed drugs and is the enzyme most
frequently implicated in clinically relevant drug–drug interactions.
Question 5. A patient taking a drug with a narrow therapeutic index develops toxicity after
starting a concurrent medication that is a potent CYP3A4 inhibitor. Which
pharmacokinetic process has been altered?
A. Absorption rate
B. Metabolic clearance
C. Renal excretion
D. Plasma protein binding
Correct Answer: B
Rationale: Potent CYP3A4 inhibition reduces metabolic clearance of the substrate drug, elevating
plasma concentrations and precipitating toxicity, especially for agents with a narrow therapeutic index.
Question 6. Which statement correctly describes zero-order elimination kinetics?
A. A constant fraction of drug is eliminated per unit time
B. Elimination rate is proportional to plasma concentration
C. Half-life remains constant across the dosing range
D. A constant amount of drug is eliminated per unit time
Correct Answer: D
Rationale: Zero-order kinetics are characterized by elimination of a fixed amount of drug per unit time,
independent of concentration, as seen with phenytoin and ethanol at therapeutic doses.
Question 7. For a drug that follows first-order kinetics, doubling the dose will
approximately double which of the following parameters at steady state?
A. Plasma concentration
B. Elimination half-life
C. Clearance
D. Volume of distribution
Correct Answer: A
Rationale: Under first-order kinetics, steady-state plasma concentration is directly proportional to dose
rate. Doubling the dose therefore doubles Css while half-life, clearance, and Vd remain unchanged.
Question 8. A medication is described as having a large volume of distribution (Vd > 100
L). What does this indicate about tissue distribution?
A. The drug is largely confined to plasma
B. The drug undergoes extensive first-pass metabolism
C. The drug is extensively distributed into extravascular tissues
D. The drug is highly water-soluble and remains in extracellular fluid
Correct Answer: C
Rationale: A large Vd indicates that the majority of the drug has left the plasma compartment and
entered tissues, often because of high lipid solubility or tissue binding.
Question 9. Which factor most strongly influences the oral bioavailability of a lipophilic
drug?
A. Gastric emptying time alone
B. Extent of first-pass hepatic metabolism
C. Renal tubular secretion
D. Plasma protein binding percentage
NURS 6521 Advanced Pharmacology Midterm Examination 2026/2027 | Verified Questions
NURS 6521 Advanced Pharmacology
Midterm Examination 2026/2027 |
Verified Questions
NURS 6521 | Advanced Pharmacology | University-Level Advanced Practice Nursing Students
100 Verified Questions | 4 Core Domains | Academic Year 2026/2027
Prepared by
NURS 6521 | Advanced Pharmacology
Midterm Comprehensive Examination Actual Exam | Academic Year 2026/2027
NURS 6521 Advanced Pharmacology Midterm Examination 2026/2027 | Verified Questions
,INTRODUCTION
This midterm comprehensive examination contains exactly 100 original verified questions designed for
University-Level Advanced Practice Nursing students enrolled in NURS 6521 Advanced Pharmacology.
The questions are distributed equally across four core domains: Pharmacologic Principles and
Pharmacokinetics (25 questions), Cardiovascular and Respiratory Pharmacology (25 questions),
Neurological, Psychiatric, and Pain Management Pharmacology (25 questions), and Endocrine,
Gastrointestinal, and Musculoskeletal Pharmacology (25 questions). Content is original and aligned with
the official NURS 6521 course objectives for the Academic Year 2026/2027, reinforcing foundational
advanced pharmacology knowledge, clinical prescribing logic, and mechanistic understanding required
for actual exam readiness and clinical proficiency.
ACTUAL QUESTIONS
Domain 1: Pharmacologic Principles and Pharmacokinetics
Question 1. A patient with hepatic impairment is prescribed a medication that undergoes
extensive first-pass metabolism. Which pharmacokinetic principle most accurately guides
dose adjustment?
A. Increase the dose because first-pass metabolism is reduced
B. Decrease the dose because bioavailability will be increased
C. Maintain the standard dose because renal clearance compensates
D. Switch to an intravenous formulation only if creatinine clearance falls below 30 mL/min
Correct Answer: B
Rationale: Hepatic impairment reduces first-pass metabolism, increasing oral bioavailability of high-
extraction drugs. Therefore the dose must be decreased to avoid toxicity. This principle is foundational
in advanced pharmacokinetics for nurse prescribers.
Question 2. Which parameter best predicts the time required for a drug to reach steady-
state plasma concentration during continuous intravenous infusion?
A. Volume of distribution
B. Clearance
C. Bioavailability
D. Elimination half-life
Correct Answer: D
Rationale: Steady state is reached after approximately four to five half-lives regardless of dose or
infusion rate. Elimination half-life is therefore the primary determinant of time to steady state.
Question 3. A highly protein-bound drug is administered to a patient with severe
hypoalbuminemia. What change in free (unbound) drug concentration is expected?
A. Increased free fraction and potentially increased pharmacologic effect
B. Decreased free fraction due to compensatory receptor upregulation
C. No change because total drug concentration remains constant
D. Decreased free fraction because hepatic synthesis of albumin increases
Correct Answer: A
Rationale: Hypoalbuminemia reduces binding sites, elevating the free fraction of highly protein-bound
drugs. The unbound concentration drives pharmacologic effect and toxicity risk, requiring careful
monitoring.
Question 4. Which cytochrome P450 enzyme is responsible for the majority of clinically
significant drug–drug interactions involving oxidative metabolism?
A. CYP2C19
B. CYP2D6
NURS 6521 Advanced Pharmacology Midterm Examination 2026/2027 | Verified Questions
, C. CYP3A4
D. CYP1A2
Correct Answer: C
Rationale: CYP3A4 metabolizes more than 50% of currently prescribed drugs and is the enzyme most
frequently implicated in clinically relevant drug–drug interactions.
Question 5. A patient taking a drug with a narrow therapeutic index develops toxicity after
starting a concurrent medication that is a potent CYP3A4 inhibitor. Which
pharmacokinetic process has been altered?
A. Absorption rate
B. Metabolic clearance
C. Renal excretion
D. Plasma protein binding
Correct Answer: B
Rationale: Potent CYP3A4 inhibition reduces metabolic clearance of the substrate drug, elevating
plasma concentrations and precipitating toxicity, especially for agents with a narrow therapeutic index.
Question 6. Which statement correctly describes zero-order elimination kinetics?
A. A constant fraction of drug is eliminated per unit time
B. Elimination rate is proportional to plasma concentration
C. Half-life remains constant across the dosing range
D. A constant amount of drug is eliminated per unit time
Correct Answer: D
Rationale: Zero-order kinetics are characterized by elimination of a fixed amount of drug per unit time,
independent of concentration, as seen with phenytoin and ethanol at therapeutic doses.
Question 7. For a drug that follows first-order kinetics, doubling the dose will
approximately double which of the following parameters at steady state?
A. Plasma concentration
B. Elimination half-life
C. Clearance
D. Volume of distribution
Correct Answer: A
Rationale: Under first-order kinetics, steady-state plasma concentration is directly proportional to dose
rate. Doubling the dose therefore doubles Css while half-life, clearance, and Vd remain unchanged.
Question 8. A medication is described as having a large volume of distribution (Vd > 100
L). What does this indicate about tissue distribution?
A. The drug is largely confined to plasma
B. The drug undergoes extensive first-pass metabolism
C. The drug is extensively distributed into extravascular tissues
D. The drug is highly water-soluble and remains in extracellular fluid
Correct Answer: C
Rationale: A large Vd indicates that the majority of the drug has left the plasma compartment and
entered tissues, often because of high lipid solubility or tissue binding.
Question 9. Which factor most strongly influences the oral bioavailability of a lipophilic
drug?
A. Gastric emptying time alone
B. Extent of first-pass hepatic metabolism
C. Renal tubular secretion
D. Plasma protein binding percentage
NURS 6521 Advanced Pharmacology Midterm Examination 2026/2027 | Verified Questions
